Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Epigenetic silencing of MIR203 in multiple myeloma.

Wong KY, Liang R, So CC, Jin DY, Costello JF, Chim CS.

Br J Haematol. 2011 Sep;154(5):569-78. doi: 10.1111/j.1365-2141.2011.08782.x. Epub 2011 Jun 28.

PMID:
21707582
2.

Epigenetic inactivation of the MIR129-2 in hematological malignancies.

Wong KY, Yim RL, Kwong YL, Leung CY, Hui PK, Cheung F, Liang R, Jin DY, Chim CS.

J Hematol Oncol. 2013 Feb 14;6:16. doi: 10.1186/1756-8722-6-16.

3.

Epigenetic inactivation of the MIR34B/C in multiple myeloma.

Wong KY, Yim RL, So CC, Jin DY, Liang R, Chim CS.

Blood. 2011 Nov 24;118(22):5901-4. doi: 10.1182/blood-2011-06-361022. Epub 2011 Oct 5.

4.

Epigenetic inactivation of the miR-124-1 in haematological malignancies.

Wong KY, So CC, Loong F, Chung LP, Lam WW, Liang R, Li GK, Jin DY, Chim CS.

PLoS One. 2011 Apr 22;6(4):e19027. doi: 10.1371/journal.pone.0019027.

5.

Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma.

Zhang Q, Wang LQ, Wong KY, Li ZY, Chim CS.

J Clin Pathol. 2015 Jul;68(7):557-61. doi: 10.1136/jclinpath-2014-202817. Epub 2015 Apr 8.

PMID:
25855800
6.
7.

Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines.

Drucker L, Tohami T, Tartakover-Matalon S, Zismanov V, Shapiro H, Radnay J, Lishner M.

Carcinogenesis. 2006 Feb;27(2):197-204. Epub 2005 Aug 19.

PMID:
16113057
8.

Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.

Kong WJ, Zhang S, Guo C, Zhang S, Wang Y, Zhang D.

Laryngoscope. 2005 Aug;115(8):1395-401.

PMID:
16094112
9.

DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors.

Salhia B, Baker A, Ahmann G, Auclair D, Fonseca R, Carpten J.

Cancer Res. 2010 Sep 1;70(17):6934-44. doi: 10.1158/0008-5472.CAN-10-0282. Epub 2010 Aug 24.

10.

4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4.

Cheng SH, Ng MH, Lau KM, Liu HS, Chan JC, Hui AB, Lo KW, Jiang H, Hou J, Chu RW, Wong WS, Chan NP, Ng HK.

Blood. 2007 Mar 1;109(5):2089-99. Epub 2006 Oct 31.

11.

Promoter methylation of the bone morphogenetic protein 6 gene in multiple myeloma.

Hashida Y, Nemoto Y, Imajoh M, Murakami M, Taniguchi A, Komatsu N, Yokoyama A, Daibata M.

Oncol Rep. 2012 Mar;27(3):825-30. doi: 10.3892/or.2011.1548. Epub 2011 Nov 11.

PMID:
22086350
12.

Epigenetic inactivation of the hsa-miR-203 in haematological malignancies.

Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, Yu L.

J Cell Mol Med. 2011 Dec;15(12):2760-7. doi: 10.1111/j.1582-4934.2011.01274.x.

13.

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.

Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R.

Blood. 2007 Feb 1;109(3):1228-32. Epub 2006 Jul 13.

14.

The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.

Hatzimichael E, Dasoula A, Shah R, Syed N, Papoudou-Bai A, Coley HM, Dranitsaris G, Bourantas KL, Stebbing J, Crook T.

Eur J Haematol. 2010 Jan 1;84(1):47-51. doi: 10.1111/j.1600-0609.2009.01344.x. Epub 2009 Sep 8.

PMID:
19737309
15.

Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma.

Wong KY, Li Z, Zhang X, Leung GK, Chan GC, Chim CS.

Mol Cancer. 2015 Sep 26;14:175. doi: 10.1186/s12943-015-0444-8.

16.

Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis.

Overmeer RM, Henken FE, Bierkens M, Wilting SM, Timmerman I, Meijer CJ, Snijders PJ, Steenbergen RD.

J Pathol. 2009 Nov;219(3):327-36. doi: 10.1002/path.2598.

PMID:
19662663
17.

Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma.

Tanaka K, Imoto I, Inoue J, Kozaki K, Tsuda H, Shimada Y, Aiko S, Yoshizumi Y, Iwai T, Kawano T, Inazawa J.

Oncogene. 2007 Sep 27;26(44):6456-68. Epub 2007 Apr 16.

PMID:
17438526
18.

MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival.

Chi J, Ballabio E, Chen XH, KuĊĦec R, Taylor S, Hay D, Tramonti D, Saunders NJ, Littlewood T, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Lawrie CH.

Biol Direct. 2011 May 18;6:23. doi: 10.1186/1745-6150-6-23.

19.

Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.

Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, Adachi Y, Endo T, Imai K, Shinomura Y.

Oncogene. 2005 Nov 24;24(53):7946-52.

PMID:
16007117
20.

[Aberrant micro RNA and epigenetic network are associated with progression from MGUS to multiple myeloma].

Handa H.

Rinsho Ketsueki. 2015 Aug;56(8):981-8. doi: 10.11406/rinketsu.56.981. Japanese.

PMID:
26345556

Supplemental Content

Support Center